600521 華海藥業
按盤價 
16.140 -0.210 (-1.284%) | 2026/06 - 中期 人民幣(K¥) | 與去年同期 比較 | 2025/12 人民幣(K¥) | 2024/12 人民幣(K¥) | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | ||
| 營業總收入 | 4,912,825 | 8.78% | 8,587,146 | 9,547,425 | 8,308,720 | 8,265,745 | |
| 減：營業總成本 | 4,348,074 | 8.66% | 8,145,905 | 7,978,739 | 7,096,900 | 6,635,694 | |
| 其中:營業成本 | 2,043,439 | 23.36% | 3,421,513 | 3,636,604 | 3,288,338 | 3,110,936 | |
| 財務費用 | 204,819 | 109.88% | 248,161 | 95,480 | 137,247 | (10,833) | |
| 資產減值損失 | (18,906) | -65.18% | (205,464) | (122,874) | (117,176) | (70,604) | |
| 公允價值變動收益 | 9,596 | -70.65% | 48,740 | (69,493) | (100,248) | 5,201 | |
| 投資收益 | 211,125 | -1,845.60% | 18,800 | (28,720) | (62,652) | (75,205) | |
| 其中：對聯營企業和合營企業的投資收益 | (35,896) | 218.36% | (18,750) | (28,660) | (27,700) | (42,191) | |
| 營業利潤 | 854,331 | 57.84% | 456,461 | 1,470,789 | 1,124,540 | 1,547,171 | |
| 利潤總額 | 902,035 | 66.16% | 443,877 | 1,463,608 | 1,100,321 | 1,508,900 | |
| 減：所得稅費用 | 134,947 | -2.00% | 216,548 | 356,145 | 283,072 | 332,890 | |
| 淨利潤 | 767,088 | 89.33% | 227,329 | 1,107,463 | 817,249 | 1,176,009 | |
| 減：非控股權益 | (3,822) | -11.71% | (39,070) | (11,518) | (13,217) | 8,251 | |
| 股東淨利潤 | 770,910 | 88.26% | 266,399 | 1,118,981 | 830,466 | 1,167,759 | |
市場價值指標 | |||||||
| 每股收益 (元) * | 0.520 | 85.71% | 0.180 | 0.770 | 0.570 | 0.810 | |
| 每股派息 (元) * | -- | -- | 0.100 | 0.250 | 0.200 | 0.240 | |
| 每股淨資產 (元) * | 6.371 | -1.36% | 6.146 | 5.903 | 5.286 | 4.925 | |
| 審計意見 # | -- | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 即時報價更新時間為 18/09/2026 16:30 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
